BioScrip Announces Proposal to Commence Exchange Offer
ELMSFORD, N.Y., May 11, 2015 /PRNewswire/ -- BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip"), today announced the commencement of an exchange offer pursuant to which it is offering to exchange up to $200,000,000 in aggregate principal amount of 8.875% Senior Notes due 2021 (the "Exchange Notes"), which have been registered under the Securities Act of 1933, as amended (the "Securities Act"), for an equal aggregate principal amount of its outstanding 8.875% Senior Notes due 2021 (the "Old Notes") that were originally issued on February 11, 2014, in a transaction exempt from registration under the Securities Act. The terms of the Exchange Notes are substantially identical to the terms of the Old Notes, except that the Exchange Notes have been registered under the Securities Act and will not be subject to the transfer restrictions and registration rights that related to the Old Notes.
The exchange offer is being made to satisfy BioScrip's obligations under a registration rights agreement entered into in connection with the issuance of the Old Notes, and does not represent a new financing transaction.
The exchange offer will expire at 5:00 p.m., New York City time, on June 9, 2015, unless extended. Tenders of Old Notes must be made before the exchange offer expires and may be withdrawn any time prior to the expiration of the exchange offer.
The terms of the exchange offer are set forth in a prospectus dated May 7, 2015, and the associated letter of transmittal. Copies of the prospectus, the associated letter of transmittal and the other exchange offer documents may be obtained from the exchange agent:
This press release is for informational purposes only and is neither an offer to buy nor a solicitation of an offer to sell any Old Notes or Exchange Notes. The exchange offer is being made only pursuant to the exchange offer prospectus and letter of transmittal, both of which are being distributed to holders of the Old Notes and have been filed with the United States Securities and Exchange Commission (the "SEC") as part of BioScrip's Registration Statement on Form S-4 (File No. 333-201925), which was declared effective on May 6, 2015.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 28 states.
SOURCE BioScrip, Inc.
Share this article